Celonic Takes the Plunge into Cell and Gene TherapiesCelonic Takes the Plunge into Cell and Gene Therapies

Celonic CEO Konstantin Matentzoglu spoke to Dan Stanton at the BPI Theater at BIO (Tuesday, 4 June 2019) about the state of the biologics contract development manufacturing organization (CDMO) industry and his company’s ambition in the space. He divulged details of the firm’s recent €50 million ($56 million) expansion at its Heidelberg, Germany site, adding 4,500 square meters of cleanroom space to feed the increased demand for biologics manufacturing services, and spoke of a similar investment at a site in Basel to propel Celonic into the burgeoning cell and gene therapy space.